Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.
Antag Therapeutics has raised $84.1M in total funding. The most recent round was Series A. The last funding was announced in December 2024.
Antag Therapeutics's investors include SR One, Novo Holdings, Versant Ventures, Vaekstfonden, Export and Investment Fund.
Antag Therapeutics is headquartered in Copenhagen, Denmark.
Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.
Antag Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Antag Therapeutics — Funding & Investors." VCBacked, December 4, 2024, https://www.vcbacked.co/company/antag-therapeutics. Accessed October 30, 2026.
VCBacked. (2024). Antag Therapeutics — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/antag-therapeutics
{{cite web |title=Antag Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/antag-therapeutics |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated